

Daraprim (pyrimethamine)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Daraprim (pyrimethamine)	3 tablets per day Initiation of therapy for toxoplasmosis : May approve an additional five tablets as a one-time loading dose.

APPROVAL CRITERIA

Requests for Daraprim (pyrimethamine) may be approved if the following criteria are met:

- I. Individual is using in combination with leucovorin; **AND**
 - II. Individual is using to for one of the following:
 - A. Individual is using to treat toxoplasmosis; **AND**
 - B. Individual is using in combination with a sulfonamide unless contraindicated or not tolerated;
- OR**
- C. Individual has a diagnosis of human immunodeficiency virus infection and is using to prevent an initial episode of toxoplasmosis (AHFS); **AND**
 - D. Individual has an intolerance or contraindication to trimethoprim-sulfamethoxazole (CDC/NIH/IDSA);
- OR**
- E. Individual has a diagnosis of human immunodeficiency virus infection and is using to prevent recurrence of toxoplasmosis (AHFS);
- OR**
- F. Individual has a diagnosis of human immunodeficiency virus infection and is using to treat or prevent recurrence of cystoisosporiasis (AHFS); **AND**
 - G. Individual has an intolerance or contraindication to trimethoprim-sulfamethoxazole (CDC/NIH/IDSA);
- OR**
- H. Individual has a diagnosis of human immunodeficiency virus infection and is using to prevent an initial episode or recurrence of *Pneumocystis jiroveci* pneumonia (AHFS); **AND**
 - I. Individual has an intolerance or contraindication to trimethoprim-sulfamethoxazole (CDC/NIH/IDSA).

Daraprim (pyrimethamine) may **not** be approved for the following:

- I. Individual has a diagnosis of megaloblastic anemia due to folate deficiency.

State Specific Mandates		
State name N/A	Date effective N/A	Mandate details (including specific bill if applicable) N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2017. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: December 7, 2017.

DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio:

Lexi-Comp, Inc.; 2017. Updated periodically. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Disease Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed: December 7, 2017.